U
Unum Therapeutics
Developing our universal Antibody-Coupled T cell Receptor (ACTR, pronounced ‘actor’) therapy to address the limitations of other T cell approaches
About Unum Therapeutics
Cogent Biosciences, operating under the domain unumrx.com, is a biotechnology startup focused on developing precision therapies for genetically defined diseases. The company operates in the healthcare and biotechnology market, serving patients suffering from diseases that are directly linked to genetic mutations. These patients represent a significant portion of the global population and are in dire need of improved therapies to enhance their quality of life and survival rates.
Read full description
Cogent's business model revolves around the discovery and development of novel, best-in-class, small molecule therapeutics. These are designed to improve upon existing drugs that have clear limitations and safety concerns. The company's primary revenue stream comes from the development and commercialization of these therapies.
The company's operations are based in Boulder, Colorado, where it has built a world-class discovery organization. Cogent is currently conducting several clinical trials, including Phase 2 SUMMIT and APEX trials, and a Phase 3 PEAK trial. The results of these trials, expected in the second half of 2023, will be crucial in determining the company's future trajectory.
Cogent is driven by a commitment to deliver novel precision therapies to patients with unmet medical needs. The company's passionate and dedicated team is focused on turning the promises of their therapies into reality, with the ultimate goal of transforming the lives of patients.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Cambridge, United States
- Employees
- 293
- Open positions
- None listed
- Dealroom signal
- 55.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Unum Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Mar 2018 | $86M | — | Undisclosed | — |
| DEBTDebt | Mar 2017 | $15M | — | Square 1 Bank | — |
Growth signals
Latest recorded traffic for Unum Therapeutics is 2.5K monthly website visits, down 68.4% over the last three months. Unum Therapeutics's team grew 12.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Atlas Venture
F-Prime
Sanofi-Genzyme BioVentures
Cowen Group
Jennison Associates
Brace Pharma
Wellington Management
New Leaf Venture Partners
Seagen
Novo Holdings
Sectoral Asset Management- SMSabby Management
Series B and later1 investor entered at this stage
Square 1 Bank
Other known investors2 additional known investors
National University of Singapore
St Jude Children’s Research Hospital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Unum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Unum Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.